Genetically modified microorganisms for heterologous production of modified forms of surfactant protein Lv-ranaspumin-1 (Lv-Rsn-1), modified forms of said surfactant protein, synthetic genes encoding said surfactant protein, expression cassettes comprising said synthetic genes, and expression vectors comprising said synthetic genes
By expressing the optimized Lv-Rsn-1 surfactant protein gene in bacteria and yeast, the problem of heterologous production of Lv-Rsn-1 in the foam of the Northeast Pepper Frog was solved, achieving stable expression and low-cost commercial application.
Patent Information
- Application Number
- CN202080094420.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-12-16
- Filing Date
- 2020-12-14
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-12-14
AI Technical Summary
Existing technologies are insufficient for the efficient heterogeneous production of Lv-Rsn-1 surfactant protein from the foam of the Northeast Pepper Frog, limiting its commercial application. Furthermore, traditional methods present high costs and ethical issues.
By constructing two genetically modified microorganisms (bacteria and yeast), the modified form of Lv-Rsn-1 surfactant protein was expressed in Escherichia coli and Saccharomyces phagnum, respectively, and heterologous production was achieved using optimized synthetic genes and expression vectors.
This achievement enables stable expression of the Lv-Rsn-1 surfactant protein in bacteria and yeast, reducing production costs, addressing ethical and environmental concerns, and providing potential for various industrial applications.
Smart Images

Figure CN115298202B_ABST
Abstract
Description
Technical Field
[0001] This patent application relates to heterologous production of a modified form of a predicted isoform of the surfactant protein Lv-ranaspumin-1 (Lv-Rsn-1) in a microorganism. The surfactant protein is produced in the Northeast Pepper Frog ( -pimenta-do-Nordeste) (Leptodactylus vastus), which therefore cannot be obtained by mining and prevents its use in different applications. More specifically, the present patent application relates to the following inventions: two synthetic genes, each encoding a modified form of the predicted amino acid sequence of an Lv-Rsn-1 isoform; two expression cassettes, each comprising one of these synthetic genes; two expression vectors, each comprising one of these synthetic genes inserted into an expression cassette; two genetically modified microorganisms (bacteria and yeast) that heterologously produce one of the modified forms of Lv-Rsn-1; and two proteins consisting of modified forms of the Lv-Rsn-1 surfactant protein. Lv-Rsn-1 has surfactant properties, emulsifying and dispersing properties, etc., and its heterologous production enables it to be used in a variety of applications and products. Background Art
[0002] Surfactants constitute a class of amphiphilic molecules, i.e., molecules whose molecular structure simultaneously presents a polar part (hydrophilic and lipophobic) and a nonpolar part (hydrophobic and lipophilic), and for this reason these molecules have the property of accumulating on the surfaces and interfaces of systems, reducing the free energy of these surfaces and interfaces. In this context, "surface" usually refers to the boundary between liquid / solid or liquid / gas, while "interface" usually refers to the boundary between two immiscible liquids.
[0003] Surfactants have several applications in agriculture, food, textiles, pharmaceuticals, cosmetics, household hygiene, oil and gas industry (de petróleoe gas), etc. These applications exploit the different activities of these surface-active molecules, the main activities being: emulsification, deemulsification, solubilization and detergency (activities related to liquid-liquid interactions); modification of wettability and dispersion (activities related to solid-liquid interactions); and foaming (activities related to liquid-gas interactions).
[0004] For example, in the oil and gas industry, surfactants are used for purposes such as: (1) bioremediation of contaminated areas, when they are used to make hydrocarbons more easily mobile and make them bioavailable to biodegrading organisms; (2) cleanup of oil spills, when they are used to disperse oil spills; (3) removal of oily residues from the inside of storage tanks; (4) control of harmful microorganisms, when they are used as biocides and antifouling agents; (5) cleaning of filter membranes, when they are used to remove mineral deposits and biofilms impregnated therein; and (6) advanced oil recovery, when they are used to make residual oil within a reservoir more easily mobile and improve recovery factors.
[0005] So-called chemical surfactants are those that are artificially synthesized from fossil precursors (petrochemicals) or plants (oleochemicals), in contrast to biosurfactants, which are those synthesized by the metabolism of living organisms. Chemical surfactants currently dominate the surfactant market, but in recent years, the use of biosurfactants has been recognized as an increasingly attractive alternative due to properties such as: (1) greater surface activity; (2) the lowest concentration required to achieve their maximum degree of surface activity (i.e., they have a low critical micelle concentration or CMC); (3) lower ecotoxicity; (4) higher biodegradability; (5) improved surface activity stability over a wider range of pH, salinity, and temperature; (6) milder production conditions; and (7) feasibility of preparation from renewable raw materials.
[0006] The total surfactant market was estimated at US$30.6 billion in 2016 and is expected to grow to US$39.8 billion by 2021, with a compound annual growth rate (CAGR) of 5.4% between 2016 and 2021. Within this total, biosurfactants accounted for US$4.2 billion in 2017 and are expected to grow to US$5.5 billion by 2022, with a CAGR of 5.6% between 2017 and 2022.
[0007] Despite all the interesting properties and many advantages reported in relation to chemical surfactants, the industrial production of biosurfactants still suffers from high preparation costs, which is currently the biggest obstacle to the wider use of biosurfactants in different fields of surfactant application. This high preparation cost is mainly due to: (1) high raw material costs, (2) low yields of the production process, and (3) costs associated with the purification of biosurfactants.
[0008] The industrial production of biosurfactants can be carried out by two different methods. The first method is to use the species in which the biosurfactant is found as a production platform. This has been the dominant method in the current biosurfactant industry, which is dominated by two types of biosurfactants, both of which are from the glycolipid class: (1) rhamnolipids (ramnolipidio, RL) produced by bacteria of the species Pseudomonas aeruginosa, and (2) sophorolipids (soforolipidio, SL) produced by yeasts of the species Starmerella (Candida) bombicola. In smaller quantities, two other types of glycolipid biosurfactants are also commercially produced: (1) mannosylerythritol lipídio (MEL), produced by yeasts of the genus Pseudozyma, and (2) cellobiose lipídio (CL), produced by yeasts of the species Ustilago maydis and Pseudozymaflocculosa. Finally, there is commercial production of isolated surfactins or lipopeptide mixtures (among them: fengycin, iturin, lichenin, mycosubtilin and surfactin), both produced by bacteria of the species Bacillus subtilis.
[0009] However, it is not always possible to use organisms of the same species in which the biosurfactant is found, and in such cases a second approach that can be adopted is the genetic transformation of some microorganisms so that they heterologously produce the biosurfactant of interest. The microbial strains most commonly used in industry as platforms for heterologous production of bioproducts are generally those for which large-scale industrial cultivation and genetic transformation techniques have been well mastered, the main strains being: bacteria of the species Bacillus subtilis, Corynebacterium (Micrococcus) glutamicum and Escherichia coli, yeasts of the species Candida albicans, Kluyveromyces lactis, Komagataella phaffii (Pichia pastoris), Saccharomyces cerevisiae and Yarrowia lipolytica, and filamentous fungi of the species Aspergillus oryzae, Aspergillus niger, Penicillium chrysogenume and Trichoderma reesei.
[0010] However, heterologous production of biosurfactants in these species presents difficulties. Most of the scientifically known biosurfactants currently produced on an industrial scale belong to the class of glycolipids and lipopeptides, which have a nonpolar part consisting of fatty acids and a polar part consisting of carbohydrates and peptides, respectively. The biosynthesis of these biosurfactants relies on complex metabolic pathways involving several genes, and in order to understand the complexity of this biosynthesis, the genes involved can be grouped into four main groups: (1) genes involved in the biosynthesis of the hydrophilic part consisting of peptides or carbohydrates; (2) genes involved in the biosynthesis of the hydrophobic part consisting of fatty acids; (3) genes involved in the covalent attachment of the hydrophilic part to the hydrophobic part; and (4) genes involved in regulating the expression of genes belonging to the other three groups.
[0011] Faced with this situation, the challenges of genetic and metabolic engineering associated with heterologous production of glycolipid and lipopeptide type biosurfactants in species traditionally used in biotechnological production processes may be expanded. This is because heterologous production in these species requires the insertion of a large number of genes, as well as the correct regulation of the expression of the inserted genes and the adequate supply of precursors to these metabolic pathways. These difficulties impair the use of the above-mentioned species, so that the industrial production of biosurfactants is currently limited to the species that naturally produce these biosurfactants.
[0012] In addition to being limited by having to be produced by microorganisms that synthesize them naturally, these biosurfactants suffer from the additional difficulty that they are produced as mixtures of different isoforms (or homologs), and these isoforms exhibit differences in their properties due to variations in the composition of both their hydrophobic and hydrophilic parts. For example, rhamnolipids can have one or two L-rhamnose-type sugars in their polar part and one or two β-hydroxylated fatty acids containing 8 to 16 even-numbered carbons in their non-polar part. The composition of biosurfactant mixtures varies greatly in terms of the proportion of each isoform, even between batches produced with the same microbial strain and under the same culture conditions. And because the properties of the different isoforms vary, the proportion of the different isoforms present in the mixture produced can affect the properties of the final product, which makes its standardization difficult.
[0013] However, there is another class of biosurfactants, the so-called surfactant proteins, whose members have the dual advantages of avoiding the need to insert several genes and making it easy to produce a single isoform. Surfactant proteins are amino acid polymers encoded by a single gene, which are expressed by the classical pathway of transcribing a DNA sequence into mRNA and translating the mRNA into protein on the ribosome according to the genetic code. In this way, a single gene can be inserted into a host microorganism (which facilitates the task of genetic transformation) and thus heterologous production of a single isoform can be performed (which facilitates standardization of the end product).
[0014] Among the known natural sources of surfactant proteins, one source explored in recent years is the foam from frog nests, which is known for their persistence in the environment. The first surfactant protein isolated from this source is the surfactant protein produced by the túngara frog (Physalaemus (=Engystomop) pustulosus). Among the six proteins isolated from the nest foam of this frog (named ranaspumin and numbered from 1 to 6), Ep-ranaspumin-2 (Ep-Rsn-2) is the only protein that shows surfactant activity, which consists of 97 amino acids and has a molecular weight of 11.0kDa (GenBank AAP48831). Ep-Rsn-2 can reduce the water / air surface tension from 72nM / m to 50nM / m at a concentration of 10μg / mL.
[0015] The applicant of the present invention has isolated a second type of surfactant protein from the nest foam of the Northeast Pepper Frog (Leptodactylus vastus). The protein was separated from the foam fluid by chromatography, and in one of the two fractions obtained, a dense and clear band with a molecular weight of about 20 kDa was detected, and it exhibited emulsifying activity at 0.1 mg / mL (emulsifying index of 57%). This protein was named Lv-ranaspumin-1 (Lv-Rsn-1).
[0016] The amino acid sequence of the Lv-Rsn-1 protein isolated from the foam fluid was deduced from the following, resulting in a predicted sequence of 217 amino acids: from information on the molecular weight of 23.5 kDa of its corresponding band in denaturing gel electrophoresis, cross-linked to sequencing by mass spectrometry of 36 peptide fragments obtained from enzymatic digestion of this band, and electron density maps obtained by X-ray crystallography. Two predicted three-dimensional structures of this Lv-Rsn-1 protein crystal are archived in the RCSB PDB (https: / / www.rcsb.org / ) with accession codes 4K82 and 4K83.
[0017] When comparing the two isoforms, Ep-Rsn-2 and Lv-Rsn-1, whose three-dimensional structures have been published, they present only 38% amino acid sequence similarity, and their three-dimensional structures are completely different: Lv-Rsn-1 has a bundle of 13 α-helices and two antiparallel β-sheets (forming a clamp), while Ep-Rsn-2 is composed of four antiparallel β-sheets with one α-helix perpendicularly wrapped around one of its faces. Therefore, although both are named ranaspumin because they come from frog nest foam, they are two clearly different proteins.
[0018] The results obtained when analyzing the L. vastus nest foam fraction containing Lv-Rsn-1 by polyacrylamide gel electrophoresis and by peptide fragment sequencing indicated the presence of other isoforms with different sizes and compositions of amino acid sequences. However, to date, neither the genome of L. vastus nor any gene encoding any isoform of Lv-Rsn-1 has been sequenced, and therefore the sequences of these other isoforms remain unknown.
[0019] Lv-Rsn-1 is a type of surfactant protein with excellent potential for different applications, and its industrial production is an obstacle that needs to be overcome in order to achieve its commercialization and application for multiple purposes. However, considering that Lv-Rsn-1 is a biosurfactant from a multicellular, conscious and environmentally regulated animal organism, it is not feasible to use the method of the producer organism itself for both technical and economic reasons and ethical and legal issues. For similar reasons, it is also not feasible to obtain Lv-Rsn-1 by mining from the foam of the Northeast Pepper Frog Nest. As far as can be confirmed at present, there is no patent related to the heterologous production of surfactant proteins from the foam of the frog nest of any species.
[0020] In view of the present disclosure, the present invention consists of two genetically modified microorganisms (bacteria and yeast) capable of heterologously producing modified forms of the Lv-Rsn-1 surfactant protein. In addition to the two genetically modified microorganisms, the present invention also contemplates the following additional inventions: (1) two proteins consisting of modified forms of the surfactant protein Lv-ranaspumin-1 (Lv-Rsn-1) predicted isoforms; (2) two synthetic genes whose sequences have been optimized for expression in bacteria and yeast, respectively, and which encode one of the two modified forms of the Lv-Rsn-1 surfactant protein predicted isoforms; (3) two bacterial and yeast expression cassettes, respectively, comprising one of the synthetic genes encoding one of the modified forms of the Lv-Rsn-1 surfactant protein predicted isoforms; and (4) two expression vectors for expression in bacteria and yeast, respectively, comprising one of the synthetic genes encoding one of the two modified forms of the Lv-Rsn-1 surfactant protein predicted isoforms. SUMMARY OF THE INVENTION
[0021] The present invention is based on the identification of the surfactant activity of a protein produced by the northeastern pepper frog (Leptodactylus vastus), Lv-ranaspumin-1 (Lv-Rsn-1), which has the potential for several industrial applications. Thus, the present invention contemplates two proteins consisting of a modified form of the predicted sequence of one of the Lv-Rsn-1 surfactant protein isoforms, neither of which occurs in nature.
[0022] Another element of the invention relates to two synthetic genes, each encoding one of the modified forms of the predicted sequences of the Lv-Rsn-1 surfactant protein isoforms and whose sequences are optimized for codon usage frequency for expression in genetically modified bacteria and eukaryotic microorganisms, respectively.
[0023] Another element of the invention relates to two expression cassettes, each comprising one of the synthetic genes encoding a modified form of the predicted sequence of the Lv-Rsn-1 surfactant protein operably linked to an active promoter, intended to be inserted into an expression vector for replication and expression in genetically modified bacteria and yeast, respectively.
[0024] Another element of the invention relates to two expression vectors, each comprising one of the synthetic genes encoding a modified form of the predicted sequence of the Lv-Rsn-1 surfactant protein isoform, targeted for replication and expression in genetically modified bacteria and yeast, respectively.
[0025] Another element of the present invention relates to two genetically modified microorganisms, bacteria and yeast, each of which is transformed with a corresponding expression vector containing an expression cassette with a synthetic gene encoding the form of the predicted sequence of the Lv-Rsn-1 surfactant protein isoform, with the goal of expressing the gene and heterologously producing the surfactant protein.
[0026] Other objects, details and advantages of the present invention will become apparent from the following drawings, sequences, descriptions and examples. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1A map of a vector for expression in bacteria is shown, pPBUFCBac-LvRsn1 (SEQ ID NO: 5), which contains a gene encoding a modified form of one of the predicted isoforms of the Lv-Rsn-1 surfactant protein (SEQ ID NO: 3). On the map, the following are shown: T7 promoter sequence (T7 promoter); lacO operator sequence (lac operator); two restriction sites for NdeI endonuclease (NdeI) and one restriction site for endonuclease EcoRI (EcoRI); polyhistidine tag coding sequence (6×His); site coding sequence for cleavage by TEV protease (TEV site); Lv-ranaspumin-1 protein coding sequence (Lv-Rsn-1) with codon frequency optimized for expression in Escherichia coli (E. coli); restriction site for XhoI endonuclease; T7 terminator sequence (T7 terminator); promoter (AmpR promoter) and coding (AmpR) sequence for ampicillin resistance marker gene; plasmid pBR322 The replication origin sequence (ori); the mobility element base (bom); the primer repressor (rop) protein coding sequence; and the promoter (lacI promoter) and coding (lacI) sequences for the lacI regulatory protein gene.
[0028] Figure 2 A map of the vector for expression in yeast, pPBUFCYea-LvRsn1 (SEQ ID NO:9), is shown, which contains a modified version of the gene for one of the predicted isoforms of the Lv-Rsn-1 surfactant protein (SEQ ID NO:7). On the map, the following are shown: AOX1 promoter sequence (AOX1 promoter); restriction site for endonuclease SacI (SacI); coding sequence of α secretion factor (α-factor secretion signal); restriction site for PstI endonuclease (PstI); Lv-ranaspumin-1 protein coding sequence with codon frequency optimized for expression in K. phaffii (Lv-Rsn-1); coding sequence for site for cleavage by TEV protease (TEV site); restriction site for NotI endonuclease (NotI); c-Myc tag coding sequence (Myc); polyhistidine tag coding sequence (6×His); terminator sequence AOX1 (AOX1 terminator); TEF1 promoter sequence (TEF1 promoter); EM7 promoter sequence (EM7 promoter); coding sequence of a marker gene for zeocin resistance (BleoR); CYC1 terminator sequence (CYC1 terminator); and pUC plasmid replication origin sequence (ori).
[0029] Figure 3 Photographs of protein electrophoresis performed with sodium dodecyl sulfate in polyacrylamide gel (SDS-PAGE) for the evaluation of the presence of a modified form of one of the predicted isoforms of the Lv-Rsn-1 surfactant protein after resolubilization of inclusion bodies produced by genetically modified bacteria and purification with a nickel column are shown. The "post-wash" sample refers to the insoluble fraction in the case of a buffer containing Triton-X-100 detergent and urea; the sample "wash" refers to the wash without the retained peak, and "MM" refers to the molecular weight marker. The arrow indicates the band corresponding to the Lv-Rsn-1 surfactant protein.
[0030] Figure 4 Shown are photographs of water / kerosene emulsification assays performed with a modified form of one of the predicted isoforms of the Lv-Rsn-1 surfactant protein produced in E. coli at 0.1 mg / mL.
[0031] Figure 5 A graph showing the surfactant effect of water / air surface tension (in mN / m) promoted by a modified form of one of the predicted isoforms of the Lv-Rsn-1 surfactant protein expressed in E. coli bacteria at different concentrations (in ppm).
[0032] Figure 6 Shown are photographs of oil dispersion assays in seawater at 1.0 mg / L of a modified form of one of the predicted isoforms of the Lv-Rsn-1 surfactant protein expressed in bacteria (and using 1.0 mg / L bovine serum albumin (BSA) as a reference).
[0033] Figure 7 Photographs showing wettability reversal assays of calcite powder impregnated with cyclohexanevaleric acid at 50 mg / L of a modified form of one of the predicted isoforms of the Lv-Rsn-1 surfactant protein expressed in bacteria. Seawater was used as a negative control and 25 mg / L Arquad C-50 cationic surfactant was used as a positive control.
[0034] Figure 8Shown are photographs of Tricine-SDS-PAGE evaluating the presence of a modified form of one of the predicted isoforms of the Lv-Rsn-1 surfactant protein in the dorna supernatant and foam of culturing genetically modified P. faffii in a 5-liter bioreactor after 24, 48, 72, and 96 hours of addition of 0.5% (v / v) methanol. MM = molecular marker; C+ = form of the Lv-Rsn-1 protein produced by E. coli; and red arrows indicate bands corresponding to a modified form of one of the isoforms of the Lv-Rsn-1 protein produced by P. faffii.
[0035] Fig. 9 Shown are photographs of water / kerosene emulsification assays performed with varying concentrations of a modified form of one of the predicted isoforms of the Lv-Rsn-1 surfactant protein produced in Phaffia fusca; the negative control consisted of BMMH medium at pH 6.0.
[0036] Fig.10 A graph showing the surfactant effect of water / air surface tension (in mN / m) promoted by different concentrations (in mg / mL) of a modified form of one of the predicted isoforms of the Lv-Rsn-1 surfactant protein expressed in Phaffia fulvidraco yeast.
[0037] Fig.11 Photographs of inverse wettability assays of calcite powder impregnated with cyclohexanevaleric acid at 50 mg / L of a modified form of one of the predicted isoforms of the Lv-Rsn-1 surfactant protein expressed in bacteria are shown. Seawater was used as a negative control, and 25 mg / L of the anionic surfactant sodium dodecyl sulfate (SDS) was used as a positive control.
[0038] Brief Description of Biological Sequence Listing
[0039] SEQ ID NO: 1 is the predicted amino acid sequence of one of the isoforms of the Lv-Rsn-1 surfactant protein present in the nest foam of the Northeast Peppered Frog (Leptodactylus massus).
[0040] SEQ ID NO:2 is a nucleotide sequence generated by reverse translation of SEQ ID NO:1.
[0041] SEQ ID NO: 3 is the nucleotide sequence generated from SEQ ID NO: 2 after optimizing its codon usage frequency for expression in bacteria (using E. coli as a reference species).
[0042] SEQ ID NO: 4 is the nucleotide sequence of SEQ ID NO: 3 to which a restriction site for endonucleases, a coding sequence for a polyhistidine tag, and a coding sequence for a TEV protease cleavage site are added.
[0043] SEQ ID NO:5 is the nucleotide sequence of a vector designated pPBUFCBac-LvRsn1 for expression in bacteria, which comprises an expression cassette containing SEQ ID NO:3.
[0044] SEQ ID NO:6 is the amino acid sequence of a modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein encoded by SEQ ID NO:4.
[0045] SEQ ID NO:7 is the nucleotide sequence generated from SEQ ID NO:2 after optimizing its codon usage frequency for expression in yeast (using Pichia pastoris as a reference species).
[0046] SEQ ID NO: 8 is the nucleotide sequence comprising the nucleotide sequence of SEQ ID NO: 7 to which a secretion factor α coding sequence, a TEV protease cleavage site coding sequence, a Myc tag coding sequence and a polyhistidine tag coding sequence are added.
[0047] SEQ ID NO:9 is the nucleotide sequence of a vector designated pPBUFCYea-LvRsn1 for expression in yeast, which comprises an expression cassette containing SEQ ID NO:7.
[0048] SEQ ID NO:10 is the amino acid sequence of a modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein encoded by SEQ ID NO:8. DETAILED DESCRIPTION OF THE INVENTION
[0050] The present invention relates to the construction of two genetically modified microorganisms that heterologously produce a modified form of one of the predicted isoforms of the surfactant protein Lv-ranaspumin-1 (Lv-Rsn-1), wherein one microorganism is a bacterium and the other is a yeast. In addition, the present invention relates to two modified forms of Lv-Rsn-1; two synthetic genes, which respectively encode these modified forms of Lv-Rsn-1; two expression cassettes, which respectively contain those synthetic genes encoding these modified forms of Lv-Rsn-1; and two expression vectors, each of which contains one of these synthetic genes encoding these modified forms of Lv-Rsn-1.
[0051] The amino acid sequence (SEQ ID NO: 1) used in the present invention corresponds to the sequence of an isoform of the Lv-Rsn-1 protein, which was predicted based on the analysis of protein extracts of the nest foam of Leptodactylus vastus by polyacrylamide gel electrophoresis and by peptide fragment sequencing. The predicted sequence of 216 amino acids and a molecular weight of 23.3 kDa of this isoform of the Lv-Rsn-1 surfactant protein was reverse translated using the reverse translation tool of the sequence manipulation kit (http: / / www.bioinformatics.org / sms2 / rev_trans.html) to obtain a nucleotide sequence encoding its amino acid sequence (SEQ ID NO: 2).
[0052] The nucleotide sequence thus obtained was then optimized for codon usage frequency both for expression in bacteria (using Escherichia coli as a reference species (SEQ ID NO: 3)) and in yeast (using Pichia pastoris as a reference species (SEQ ID NO: 7)) using the Codon Optimization Tool from Integrated DNA Technologies (http: / / www.idtdna.com).
[0053] A nucleotide sequence optimized for expression in bacteria (SEQ ID NO:3) was used to design a gene in which nucleotides were added downstream and upstream of SEQ ID NO:3, consisting of a site for endonucleases (to facilitate its insertion into an expression vector) and a sequence encoding an additional amino acid sequence (to facilitate purification of the expressed protein).
[0054] The gene is artificially synthesized, and both the synthetic gene and the vector for expression in bacteria are digested with two endonucleases (so that the gene is inserted in the correct direction relative to the promoter in the expression cassette), and then connected by DNA ligase. The expression vector thus obtained contains an expression cassette having a synthetic gene operably linked to a promoter active in bacteria, and the expression cassette can be removed from the vector by digestion with endonucleases and ligation with DNA ligase and inserted into another vector for expression in bacteria.
[0055] A bacterial strain is genetically transformed with an expression vector containing a synthetic gene encoding a modified form of a predicted isoform of the Lv-Rsn-1 surfactant protein. The genetically modified bacteria are cultured in an appropriate medium to allow them to propagate and express this form of Lv-Rsn-1.
[0056] For yeast, a nucleotide sequence optimized for expression in yeast (SEQ ID NO:7) was used to design a gene in which nucleotides were added downstream and upstream of SEQ ID NO:3, consisting of a site for endonucleases (to facilitate its insertion into an expression vector) and a sequence encoding an additional amino acid sequence (to facilitate purification of the expressed protein).
[0057] The gene is artificially synthesized, and both the synthetic gene and the vector for expression in yeast are digested with two endonucleases (so that the gene is inserted in the correct direction relative to the promoter in the expression cassette), and then ligated by DNA ligase. The expression vector thus obtained contains an expression cassette having a synthetic gene operably linked to a promoter active in bacteria, and the expression cassette can be removed from the vector and inserted into another vector for expression in yeast by digestion with endonucleases and ligation with DNA ligase.
[0058] A yeast strain is genetically transformed with an expression vector containing a synthetic gene encoding a modified form of a predicted isoform of the Lv-Rsn-1 surfactant protein. The genetically modified yeast is cultured in an appropriate medium to allow it to propagate and express this form of Lv-Rsn-1. Example
[0059] The present invention can be better understood by the following examples. It should be noted that the present invention is not limited to the embodiments mentioned and can be used in all applications described or any other equivalent variations.
[0060] Example 1 : Obtaining a vector for producing Lv-Rsn-1 in bacteria
[0061] A nucleotide sequence encoding an amino acid sequence of an isoform of the Lv-Rsn-1 surfactant protein and optimized for expression in bacteria (SEQ ID NO:3) was supplemented with nucleotides to produce a synthetic gene (SEQ ID NO:4) having the following composition when read in the 5' to 3' direction: (1) a restriction site sequence for EcoRI endonuclease with thymine added at the 3' end (5'-GAATTCT-3'); (2) a sequence encoding a TEV protease cleavage site (ENLYFQGS) (5'-GAAAACTTGTATTTCCAGGGCAGC-3'); (3) a restriction site sequence for NdeI endonuclease (5'-CATATG-3'); (4) a start codon (5'-ATG-3'); (5) a sequence encoding an amino acid sequence of a predicted isoform of the Lv-Rsn-1 surfactant protein with a codon frequency optimized for expression in bacteria (SEQ ID NO:4). NO:3); (6) a stop codon (5'-TAA-3'); and (7) a restriction site sequence for XhoI endonuclease (5'-CTCGAG-3').
[0062] Both the synthetic gene (SEQ ID NO: 4) and the vector for expression in bacteria were digested with EcoRI and XhoI endonucleases and subsequently ligated by DNA ligase. The final sequence of the expression vector named pPBUFCBac-LvRsn1 (SEQ ID NO: 5) is Figure 2 Shown in.
[0063] The modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein encoded by the gene present in the expression vector pPBUFCYea-LvRsn1 (SEQ ID NO: 5) has 236 amino acids and a molecular weight of 25.8 kDa (SEQ ID NO: 6), which differs from the predicted isoform in that a twenty amino acid sequence is added to its N-terminal portion, which includes a polyhistidine tail (HHHHHH) and a site for cleavage by TEV protease (ENLYFQG). When this modified form of the isoform of the Lv-Rsn-1 surfactant protein is digested by TEV protease, it differs from the predicted isoform in that five amino acids (GSHMM) are present in its N-terminal portion.
[0064] Example 2 : Obtaining genetically modified bacteria
[0065] The E. coli bacterial strain was genetically transformed by electroporation with the pPBUFCBac-LvRsn1 vector (SEQ ID NO: 5). The strain used was a strain derived from the E. coli K-12 strain, and the source strain was: (1) auxotrophic for leucine amino acid and sensitive to kanamycin antibiotics; (2) it had mutations in the glutathione reductase (glutationa redutase, gor) and thioredoxin reductase (tiorredoxina redutase, trxB) genes; and (3) it had genes that conferred resistance to tetracycline antibiotics.
[0066] E. coli cells were washed 3 times with 10% (m / v) glycerol solution to make them electrocompetent, and then 1.0 μL of a solution containing pPBUFCBac-LvRsn1 vector (50 ηg / μL) was added. After the cell mixture and the vector were kept on ice for 1 minute, the mixture was transferred to a 0.2 cm electroporation cuvette and subjected to 2.5 kV of electric shock. After electroporation, 960 μL of SOC medium (20 g / L tryptone; 5 g / L yeast extract; 10 mM NaCl; 2.5 mM KCl; 10 mM MgCl2; 10 mM MgSO4; and 20 mM glucose) was added, and the mixture was incubated at 150 rpm and 37°C for 1 hour. After the incubation time, 50 μL of the culture was inoculated into a Petri dish containing LB agar medium (10 g / L tryptone; 5 g / L yeast extract; 5 g / L NaCl; and 15 g / L agar).
[0067] The obtained colonies were then cultured in LB medium supplemented with 12.5 μg / mL of tetracycline (to select only cells of this lineage and prevent the growth of contaminating bacteria) and 100 μg / mL of ampicillin (to select only transformed cells and prevent the growth of non-transformed cells).
[0068] The genetic transformation of the obtained colonies with the expression vector pPBUFCBac-LvRsn1 was evaluated by extracting DNA from these colonies, digesting the extracted DNA with restriction enzymes EcoRI and XhoI, and performing electrophoresis in 1% (m / v) agarose gel to verify the presence of the expected 692 bp fragment. The genetic transformation of E. coli with the expression vector pPBUFCBac-LvRsn1 and the replication and stable inheritance of pPBUFCBac-LvRsn1 over several generations were confirmed in several colonies.
[0069] Example 3 :Producing Lv-Rsn-1 by genetically modified bacteria
[0070] E. coli cells transformed with the pPBUFCBac-LvRsn1 vector were cultured in LB medium supplemented with isopropyl-β-D-1-thiogalactopiranoside (IPTG), a structural analog of allolactose that interacts with the lacI protein, causing its separation from the lacO operon and thereby inducing the expression of the gene encoding a modified form of the Lv-Rsn-1 surfactant protein isoform.
[0071] The pre-inoculum of genetically transformed cells was obtained by transferring the isolated colonies to 10 mL of LB broth supplemented with two antibiotics (12.5 μg / mL tetracycline and 100 μg / mL ampicillin) and then incubating at 250 rpm and 37 ° C for 16 hours. Then, the culture of 1 mL volume was transferred to a bottle containing 100 mL of LB medium supplemented with 100 μg / mL ampicillin and incubated at 37 ° C and 250 rpm until the exponential growth phase was reached (optical density of 0.5 to 0.7 at 600 nm). The bottle was left standing at room temperature for 15 minutes. Then, IPTG was added to a final concentration of 0.5 mM, and the culture was incubated at 200 rpm and 37 ° C for 3 hours. After this period, the culture was centrifuged at 7,800 g for 13 minutes at 4 ° C, the supernatant was discarded, and the precipitate was washed with 0.1 M NaCl and centrifuged at 7,800 g for 1 hour at 4 ° C.
[0072] To purify the modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein whose expression was induced by IPTG, the cells were resuspended in 5 mL of resuspension buffer (50 mM Tris-HCl pH 8.0 and 150 mM NaCl) and sonicated in an ice bath for three cycles of 5 minutes each and an amplitude of 40%. After sonication, the cells were centrifuged at 15,000 g for 45 minutes at 4°C to separate the soluble (supernatant) and insoluble (precipitate) fractions.
[0073] The modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein was purified from the insoluble fraction (precipitate containing inclusion bodies) using a resolubilization and renaturation protocol. To this end, the insoluble fraction was resuspended in a wash buffer (100 mM Tris-HCl pH 8.0, 5 mM EDTA, 5 mM DTT, 2 M urea and 2% Triton X-100) and centrifuged at 22,000 g for 30 minutes at 4°C. The preparation was analyzed by 15% SDS-PAGE to verify whether two washes with a buffer containing Triton X-100 detergent and urea were sufficient to extract most of the modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein from the inclusion bodies.
[0074] The modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein was purified from the supernatant washed with Triton X-100 and urea by dialysis against ultrapure water and then applied to a nickel column containing silica resin previously equilibrated with 50 mM Tris-HCl pH 8.0 and 100 mM NaCl. Elution of Lv-Rsn-1 was performed using an elution buffer corresponding to 50 mM Tris-HCl pH 8.0; 500 mM NaCl; and 250 mM imidazole.
[0075] Analysis by SDS-PAGE demonstrated that the modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein was indeed expressed in E. coli. Figure 3 The electrophoresis results of the protein extracts after resolubilization of the inclusion bodies and nickel column purification process (by interacting with the polyhistidine tail present in the modified form of Lv-Rsn-1) are shown. "After washing" refers to the insoluble fraction with a buffer containing Triton-X-100 detergent and urea; "wash" refers to the wash without the retained peak; and "MM" refers to the molecular marker. The arrow indicates the band corresponding to Lv-Rsn-1.
[0076] Cultivation of bacteria genetically transformed with the pPBUFCBac-LvRsn1 vector (SEQ ID NO: 5) showed that the vector was stably inherited over several generations of cells, which began to replicate the vector and express the gene encoding a modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein in the presence of IPTG, and this protein was concentrated in inclusion bodies.
[0077] It is clear from the above disclosure that the invention discussed technically enables the heterologous production of modified forms of the predicted isoforms of the Lv-Rsn-1 surfactant protein in bacteria, providing a solution to the prior art in that it allows the production of such animal-derived surfactant proteins without the need to collect and extract foam from the nests of the Northeast Peppered Frog (Leptodactylusvastus) and all the costs and environmental impacts that would otherwise be incurred by such collection and extraction.
[0078] Example 4 :Activity of Lv-Rsn-1 produced by bacteria
[0079] Modified forms of the predicted isoform of the Lv-Rsn-1 surfactant protein expressed in genetically transformed E. coli cells were purified and subjected to various assays to evaluate their emulsification, water / air surface tension reducing activity, oil dispersibility, and wettability inversion.
[0080] The modified forms of the predicted isoforms of the Lv-Rsn-1 surfactant protein expressed in Escherichia coli emulsified water / kerosene mixtures at concentrations ranging from 0.01 to 10.0 mg / mL. Figure 4 Shown in.
[0081] The modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein expressed in E. coli reduced the water / air surface tension. Lv-Rsn-1 at a concentration of 0.15 mg / mL reduced the surface tension of water from 72 mN / m to 39 mN / m, such as Figure 5 Shown in.
[0082] The modified forms of the predicted isoforms of the Lv-Rsn-1 surfactant protein expressed in Escherichia coli at a concentration of 1.0 mg / L had an effect on the dispersion of spilled oil in seawater. Figure 6 The same Figure 6 Also shown is the oil layer before addition of Lv-Rsn-1, as well as the lack of dispersing activity of bovine serum albumin (BSA) protein (also at a concentration of 1 mg / L) used as a reference.
[0083] The wettability of the modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein expressed in E. coli on calcite powder (CaCO3) impregnated with cyclohexanevaleric acid was reversed at a concentration of 50 mg / L. Figure 7 The wettability reversal was measured by the presence of a greater amount of calcite powder at the bottom of the test tube compared to the negative control (sea water).
[0084] It is clear from the above disclosure that modified forms of the predicted isoforms of the Lv-Rsn-1 surfactant protein expressed in E. coli act as surfactants, emulsifiers, dispersants and wettability reversing agents and can be applied for different purposes related to these activities.
[0085] Example 5 : Obtaining a vector for producing Lv-Rsn-1 in yeast
[0086] Nucleotides were added to a nucleotide sequence optimized for expression in yeast (SEQ ID NO:7) to produce a synthetic gene (SEQ ID NO:8) having the following composition when read in the 5' to 3' direction: (1) a restriction site for PstI endonuclease (5'-CTGCAG-3'); (2) two nucleotides (5'-GN-3') that place the Lv-Rsn-1 coding sequence in the same translation frame as the α secretory factor; (3) a sequence encoding the Lv-Rsn-1 surfactant protein (SEQ ID NO:7) with a codon frequency optimized for yeast expression; (4) a sequence encoding a TEV protease cleavage site (ENLYFQG) ((5'-GAGAACCTTTACTTTCAGGGA-3')); and (5) a restriction site for NotI endonuclease (5'GCGGCCGC-3').
[0087] Both the synthetic gene (SEQ ID NO: 79) and the vector for expression in bacteria were digested with PstI and NotI endonucleases and subsequently ligated by DNA ligase. The final sequence of the expression vector named pPBUFCYea-LvRsn1 (SEQ ID NO: 9) is Figure 3 Shown in.
[0088] The modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein encoded by the gene present in the expression vector pPBUFCYea-LvRsn1 (SEQ ID NO: 9) has 341 amino acids and a molecular weight of 36.7 kDa (SEQ ID NO: 10), which differs from the predicted isoform in that the following are added: secretion factor α (plus two amino acids), and a site for cleavage by TEV protease (plus six amino acids) at its N-terminal portion, a c-Myc tag (plus five amino acids) and a polyhistidine tail at the C-terminal portion. When this modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein is digested by TEV protease, it differs from the predicted isoform in that 91 amino acids are present in its N-terminal portion and 6 amino acids are present in its C-terminal portion.
[0089] Example 6: Obtaining genetically modified yeast
[0090] The yeast strain of the species Phaffia spp. was genetically transformed with the vector pPBUFCYea-LvRsn1 (SEQ ID NO: 9) by electroporation. The strain used was the Phaffia spp. GS115 / ATCC 20864 strain, and this strain is auxotrophic for the amino acid histidine (HIS4 – ) and have genes active for AOX1 and AOX2 (Mut + ), allowing them to use methanol as a nutrient.
[0091] Phaffia cells were prepared by inoculating isolated colonies in 5.0 mL YPD medium (10 g / L yeast extract; 20 g / L peptone; and 20 g / L glucose) and incubating at 250 rpm for 16 hours at 30 ° C. Then, 250 μL of the culture was transferred to 500 mL YPD broth in a 2.0 L container and incubated at 250 rpm for about 16 hours at 30 ° C until an optical density of 1.3 to 1.6 at 600 nm was obtained. Then, the culture was centrifuged at 1,500 g for 5 minutes at 4 ° C. The supernatant was discarded and the pellet containing the cells was gently resuspended in 500 ml of ice-cold ultrapure water. Then, the cells were centrifuged again and the pellet was resuspended in 250 ml of ice-cold ultrapure water. The cells were centrifuged and the pellet was resuspended in 20 ml of ice-cold 1.0 M D-sorbitol. Finally, cells were centrifuged and resuspended in 1.0 ml ice-cold 1.0 M D-sorbitol to generate electrocompetent cells for genetic transformation.
[0092] In preparation for genetic transformation, the vector pPBUFCYea-LvRsn1 (SEQ ID NO: 9) was linearized with SacI endonuclease, and the linearized vector was subsequently purified using a potassium acetate precipitation protocol. To this end, 3.0 M potassium acetate at pH 5.5 was added to a final concentration of 0.3 M, followed by 2 volumes of 100% ethanol and incubated at -20°C for 30 minutes. The mixture was then centrifuged at 12,000 g for 10 minutes at 4°C, the precipitate was washed with 70% ethanol and centrifuged again. After the plasmid was dried at 37°C for 10 minutes, it was resuspended in ultrapure water, quantified by spectrophotometry, and stored in a refrigerator at -20°C.
[0093] For genetic transformation, a 90 μL volume of a solution containing electrocompetent P. philafii cells was mixed with 5 to 10 μg of linearized pPBUFCYea-LvRsn1 vector DNA (SEQ ID NO: 9) in a 600 μL microtube and the final volume was transferred to a 0.2 cm electroporation cuvette precooled on ice. The cuvette containing cells and linearized vector was incubated on ice for 5 minutes and then subjected to a 2.5 kV pulse in an electroporator. 1.0 mL of ice-cold 1.0 M D-sorbitol was immediately added to the cuvette and the contents were then transferred to a 15 mL tube. The tube was incubated at 30°C without stirring for 2 hours. Then, a 200 μL volume of the tube contents was inoculated onto a plate containing YDPS agar medium (10 g / L yeast extract; 20 g / L peptone, 20 g / L glucose; 182.2 g / L D-sorbitol and 15 g / L agar) supplemented with 100 μg / mL zeocin antibiotic. The plate was incubated in an oven at 30°C for 3 to 10 days until colonies appeared. The transformed clones were cultured in YPD medium and stored at -80°C after supplementation with 20% (v / v) glycerol. The transformed clones were sequentially subjected to increasing concentrations of zeocin (500, 1000 and 2000 μg / mL) in YPD agar medium to select transformants containing multiple copies of the pPBUFCYea-LvRsn1 vector (SEQ ID NO: 9).
[0094] To determine the success of genetic transformation, genomic DNA was extracted from cell colonies resistant to 2,000 μg / mL zeocin using the hexadecyl trimethylammonium bromide (CTAB) protocol. At the end of the extraction, the obtained DNA was eluted in 50 μl 10 mM Tris-HCl pH 8.0 supplemented with 20 μg / μL RNAse. The samples were quantified and evaluated by absorbance measurements at 230, 260 and 280 nm in a spectrophotometer and then stored in a refrigerator at -20 ° C. The presence of a gene encoding a modified form of the Lv-Rsn-1 surfactant protein in the transformed clone was detected using the polymerase chain reaction (PCR) technique using primers AOX1-fwd (5'-GACTGGTTCCAATTGACAAGC-3') and AOX1-rev (5'-GCAAATGGCATTCTGACATCC-3'). The PCR reaction was carried out in a final volume of 25 μL containing: 50 ng genomic DNA; 20 mM Tris-HCl (pH 8.4); 3.0 mM MgCl2; 0.2 mM of each dNTP; 0.5 μM of each primer; and 1.0 unit of Taq DNA polymerase. The reaction was carried out in a thermal cycler, programmed for an initial denaturation step (5 minutes at 94°C), followed by 30 cycles (1 minute at 94°C, 1 minute at 52°C, and 1.5 minutes at 72°C). The last cycle was followed by a final extension of 10 minutes at 72°C. The PCR products were visualized in 1.0% (m / v) agarose gel electrophoresis, stained with SYBR Green and referenced with a 1 kb marker. The genetic transformation of P. philafi with the expression vector pPBUFCYea-LvRsn1 (SEQ ID NO: 9) and the stable inheritance of this transformation over several generations were determined.
[0095] Example 7 :Determination of the production of Lv-Rsn-1 in yeast
[0096] Phaffia cells transformed with the pPBUFCYea-LvRsn1 vector (SEQ ID NO: 9) were cultured at 30° C. on plates containing YPD agar medium (10 g / L yeast extract; 20 g / L peptone; 20 g / L glucose; and 15 g / L agar) supplemented with 100 μg / mL of the antibiotic zeocin. For pre-inoculation, pure colonies were cultured in 200 mL BMGH medium (13.4 g / L yeast extract containing ammonium sulfate but no amino acids; 10 mL / L glycerol; 100 mL / L phosphate buffer 1.0 M pH 6.0; 2.0 mL / L 0.02% biotin; 10 mL / L 0.4% histidine; and 100 μg / mL zeocin) at 29° C. at 250 rpm for 16 hours until an optical density of about 2.0 at 600 nm was reached. Then, the culture was centrifuged at 3,500 rpm for 5 minutes, and the pellet was washed twice with BMMH medium (13.4 g / L yeast extract containing ammonium sulfate but not amino acids; 100 mL / L phosphate buffer 1.0 M pH 6.0; 2.0 mL / L 0.02% biotin; 10 mL / L 0.4% histidine; and 0.5% v / v methanol) to remove glycerol present in the BMGH medium used in the pre-inoculation.
[0097] After this step, the cells were resuspended and inoculated into a 500 mL bottle containing 50 mL BMMH with an optical density of 1.0 at 600 nm. When the culture was supplemented with 0.5% (v / v) methanol, the culture was incubated at 29° C. with stirring at 250 rpm for 96 hours, and the optical density at 600 nm was monitored every 24 hours. At the end of 96 hours, the culture was centrifuged at 3,000 g for 5 minutes.
[0098] The expression of the modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein by P. phila was monitored by Tricine-SDS-PAGE. Before being applied to the electrophoresis gel, the sample from the supernatant was precipitated with acetone, and the sample from the precipitate (0.3 mg) was mixed with 0.3 mL of sample buffer (2 mL SDS; 1.2 mL glycerol; 0.2 mL β-mercaptoethanol; 1.0 mg Coomassie Brilliant Blue G-250; and 0.5 mL Tris-HCl pH 6.8, 10 mL final volume) and incubated at 100° C. for 10 minutes. The results obtained indicate that P. phila expresses the modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein, and this feature is maintained over several generations.
[0099] Subsequently, the same P. philafi cells transformed with the pPBUFCYea-LvRsn1 vector were cultured in a bioreactor with a volume of 5.0 L. For the pre-inoculum, pure colonies were cultured in six 2.0 L bottles containing 200 mL of BMGH medium supplemented with 100 μg / mL ampicillin at 29°C and 250 rpm for 16 hours until an optical density at 600 nm of about 2.0 was reached. These cultures were combined, the final volume was centrifuged at 3,000 rpm for 5 minutes, and the pellet was washed twice with BMMH expression medium to remove the remaining glycerol. Subsequently, the cells were resuspended in 100 ml of BMMH medium and this volume was transferred to the bioreactor so that the optical density at 600 nm was about 1.5.
[0100] Batch cultures were grown using a maximum volume of 3.0 L of BMMH expression medium supplemented with 100 μg / mL zeocin at 29°C, 500 rpm and 1 vvm aeration. The initial optical density at 600 nm was recorded and the culture received 0.5% (v / v) methanol. This operation was repeated every 24 hours until 96 hours. Every 24 hours, the volume of foam overflowing from the Mariotte bottle was collected and connected to the bioreactor to collect the foam overflowing from the bucket. The liquefied foam was centrifuged at 9,000 rpm for 10 minutes at 4°C. The foam protein concentration was quantified and the protein spectrum was analyzed by Tricine-SDS-PAGE 15%. The results obtained showed that the modified form of Lv-Rsn-1 produced by Phaffia fusca in a 5.0 L bioreactor was concentrated in the foam, as shown in Figure 2. Figure 8 It can be seen in.
[0101] Example 8 :Activity of Lv-Rsn-1 produced by yeast
[0102] Modified forms of the predicted isoform of the Lv-Rsn-1 surfactant protein expressed in genetically transformed Phaffia calvaria cells cultured in a 5.0 L bioreactor were purified and subjected to various assays to evaluate their emulsification activity, reduction of water / air surface tension, and wettability inversion.
[0103] The emulsification of water / kerosene mixtures by modified forms of the predicted isoforms of the Lv-Rsn-1 surfactant protein expressed in Phaffia fusca at concentrations ranging from 0.03 to 0.24 mg / mL was Fig. 9 Shown in.
[0104] The modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein expressed in Phaffia fusca reduces the water / air surface tension. Lv-Rsn-1 at a concentration of 0.24 mg / mL reduces the surface tension of water from 72 mN / m to 35 mN / m, as shown in Fig.10 as shown in .
[0105] The wettability of the modified form of the predicted isoform of the Lv-Rsn-1 surfactant protein expressed in Phaffia fusca on calcite powder (CaCO3) impregnated with cyclohexanevaleric acid was reversed at a concentration of 50 mg / L. Fig.11 The wettability reversal was measured by the presence of a greater amount of calcite powder at the bottom of the test tube compared to the negative control (sea water). Sodium dodecyl sulfate (SDS) at a concentration of 2,500 mg / L was used as a positive control.
[0106] It is clear from the above disclosure that modified forms of the predicted isoforms of the Lv-Rsn-1 surfactant protein expressed in Phaffia fusca act as surfactants, emulsifiers, dispersants and wettability reversing agents and can be applied for different purposes related to these activities.
[0107] A person skilled in the art will understand that numerous variations are possible within the scope of protection of the present application and therefore reinforce the fact that the invention is not limited to the specific configurations and embodiments described above.
[0108]
[0109]
[0110]
[0111]
[0112]
[0113]
[0114]
[0115]
[0116]
[0117]
[0118]
[0119]
[0120]
[0121]
[0122]
[0123]
[0124]
[0125]
[0126]
[0127]
[0128]
[0129]
[0130]
[0131]
[0132]
[0133] Biological Sequence Listing <110> Petróleo Brasileiro SA - Petrobras <120> Genetically modified microorganisms for heterologous production of modified forms of surfactant protein Lv-Ranaspumin-1 (Lv-Rsn-1), modified forms of said surfactant protein, synthetic genes encoding said surfactant protein, expression cassettes comprising said synthetic genes, and expression vectors comprising said synthetic genes <160> 10 <210> 1 <211> 216 <212> PRT <213> Leptodactylus vastus <223> Predicted sequence of one of the Lv-ranaspumin-1 isoforms <400> 1 Leu Leu Glu Gly Phe Leu Val Gly Gly Gly Val Pro Gly Pro Gly Thr 1 5 10 15 Ala Cys Leu Thr Lys Ala Leu Lys Asp Ser Gly Asp Leu Leu Val Glu 20 25 30 Leu Ala Val Ile Ile Cys Ala Tyr Gln Asn Gly Lys Asp Leu Gln Glu 35 40 45 Gln Asp Phe Lys Glu Leu Lys Glu Leu Leu Glu Arg Thr Leu Glu Arg 50 55 60 Ala Gly Cys Ala Leu Asp Asp Ile Val Ala Asp Leu Gly Leu Glu Glu 65 70 75 80 Leu Leu Gly Ser Ile Gly Val Ser Thr Gly Asp Ile Ile Gln Gly Leu 85 90 95 Tyr Lys Leu Leu Lys Glu Leu Lys Ile Asp Glu Thr Val Phe Asn Ala 100 105 110 Val Cys Asp Val Thr Lys Lys Met Leu Asp Asn Lys Cys Leu Pro Lys 115 120 125 Ile Leu Gln Gly Asp Leu Val Lys Phe Leu Asp Leu Lys Tyr Lys Val 130 135 140 Cys Ile Glu Gly Gly Asp Pro Glu Leu Ile Ile Lys Asp Leu Lys Ile 145 150 155 160 Ile Leu Glu Arg Leu Pro Cys Val Leu Gly Gly Val Gly Leu Asp Asp 165 170 175 Leu Phe Lys Asn Ile Phe Val Lys Asp Gly Ile Leu Ser Phe Glu Gly 180 185 190 Ile Ala Lys Pro Leu Gly Asp Leu Leu Ile Leu Val Leu Cys Pro Asn 195 200 205 Val Lys Asn Ile Asn Val Ser Ser 210 215 <210> 2 <211> 648 <212> DNA <213> Artificial sequence <220> <221> CDS <222> (1)...(648) <223> Coding sequence of one of the Lv-ranaspumin-1 isoforms obtained after reverse translation of the predicted amino acid sequence <400> 2 ctg ctg gaa ggc ttt ctg gtg ggc ggc ggc gtg ccg ggc ccg ggc acc 48 Leu Leu Glu Gly Phe Leu Val Gly Gly Gly Val Pro Gly Pro Gly Thr 1 5 10 15 gcg tgc ctg acc aaa gcg ctg aaa gat agc ggc gat ctg ctg gtg gaa 96 Ala Cys Leu Thr Lys Ala Leu Lys Asp Ser Gly Asp Leu Leu Val Glu 20 25 30 ctg gcg gtg att att tgc gcg tat cag aac ggc aaa gat ctg cag gaa 144 Leu Ala Val Ile Ile Cys Ala Tyr Gln Asn Gly Lys Asp Leu Gln Glu 35 40 45 cag gat ttt aaa gaa ctg aaa gaa ctg ctg gaa cgc acc ctg gaa cgc 192 Gln Asp Phe Lys Glu Leu Lys Glu Leu Leu Glu Arg Thr Leu Glu Arg 50 55 60 gcg ggc tgc gcg ctg gat gat to gtg gcg gat ctg ggc ctg gaa gaa 240 Ala Gly Cys Ala Leu Asp Asp Ile Val Ala Asp Leu Gly Leu Glu Glu 65 70 75 80 ctg ctg ggc agc att ggc gtg agc acc ggc gat att att cag ggc ctg 288 Leu Leu Gly Ser Ile Gly Val Ser Thr Gly Asp Ile Ile Gln Gly Leu 85 90 95 tat aaa ctg ctg aaa gaa ctg aaa to gat gaa acc gtg ttt aac gcg 336 Tyr Lys Leu Leu Lys Glu Leu Lys Ile Asp Glu Thr Val Phe Asn Ala 100 105 110 gtg tgc gat gtg acc aaa aaa atg ctg gat aac aaa tgc ctg ccg aaa 384 Val Cys Asp Val Thr Lys Lys Met Leu Asp Asn Lys Cys Leu Pro Lys 115 120 125 att ctg cag ggc gat ctg gtg aaa ttt ctg gat ctg aaa tat aaa gtg 432 Ile Leu Gln Gly Asp Leu Val Lys Phe Leu Asp Leu Lys Tyr Lys Val 130 135 140 tgc to go ggc ggc gat ccg gaa ctg to to aaa gat ctg aaa to 480 Cys Ile Glu Gly Gly Asp Pro Glu Leu Ile Ile Lys Asp Leu Lys Ile 145 150 155 160 to ctg gaa cgc ctg ccg tgc gtg ctg ggc ggc gtg ggc ctg gat gat 528 Ile Leu Glu Arg Leu Pro Cys Val Leu Gly Gly Val Gly Leu Asp Asp 165 170 175 ctg ttt aaa aac att ttt gtg aaa gat ggc att ctg agc ttt gaa ggc 576 Leu Phe Lys Asn Ile Phe Val Lys Asp Gly Ile Leu Ser Phe Glu Gly 180 185 190 att gcg aaa ccg ctg ggc gat ctg ctg att ctg gtg ctg tgc ccg aac 624 Ile Ala Lys Pro Leu Gly Asp Leu Leu Ile Leu Val Leu Cys Pro Asn 195 200 205 gtg aaa aac att aac gtg agc agc 648 Val Light Asn Ile Asn Val Ser Ser 210 215 <210> 3 <211> 651 <212> DNA <213> Artificial sequence <220> <221> CDS <222> (1)...(651) <223> Codon frequency optimization of SEQ ID NO: 2 for expression in bacteria and addition of ATG start codon <400> 3 atg ctg ctg gaa ggt ttt ctg gtt ggg ggc ggt gtt ccg ggt cca ggc 48 Met Leu Leu Glu Gly Phe Leu Val Gly Gly Gly Val Pro Gly Pro Gly 1 5 10 15 acg gcc tgc ttg acg aag gct ctg aaa gat agc ggt gac ctg ctg gtg 96 Thr Ala Cys Leu Thr Lys Ala Leu Lys Asp Ser Gly Asp Leu Leu Val 20 25 30 gag tta gcg gtt att att tgt gca tac cag aat ggc aaa gac ctt cag 144 Glu Leu Ala Val Ile Ile Cys Ala Tyr Gln Asn Gly Lys Asp Leu Gln 35 40 45 gag cag gac ttc aaa gaa ctg aag gaa ttg ctg gaa cgt aca ttg gaa 192 Glu Gln Asp Phe Lys Glu Leu Lys Glu Leu Leu Glu Arg Thr Leu Glu 50 55 60 cgt gcc ggt tgt gcc ctc gat gat to gtg gcc gat tta ggt ctg gaa 240 Arg Ala Gly Cys Ala Leu Asp Asp Ile Val Ala Asp Leu Gly Leu Glu 65 70 75 80 gaa ctg ctg ggc tcc atc ggc gtt agt acc ggc gat att atc cag ggt 288 Glu Leu Leu Gly Ser Ile Gly Val Ser Thr Gly Asp Ile Ile Gln Gly 85 90 95 ctg tat aaa ctg ttg aag gag tta aaa atc gac gag acc gtc ttt aat 336 Leu Tyr Lys Leu Leu Lys Glu Leu Lys Ile Asp Glu Thr Val Phe Asn 100 105 110 gcg gtc tgc gat gtg acc aaa aaa atg ctg gat aac aag tgc tta ccg 384 Ala Val Cys Asp Val Thr Lys Lys Met Leu Asp Asn Lys Cys Leu Pro 115 120 125 aaa att ctg caa gga gat ctg gta aag ttc ctt gat ctg aag tat aaa 432 Lys Ile Leu Gln Gly Asp Leu Val Lys Phe Leu Asp Leu Lys Tyr Lys 130 135 140 gtt tgt att gaa ggt ggc gat cca gaa ctg att att aag gat ctg aaa 480 Val Cys Ile Glu Gly Gly Asp Pro Glu Leu Ile Ile Lys Asp Leu Lys 145 150 155 160 atc atc ctg gaa cgg ctt ccg tgt gtg ttg ggt gga gtc ggt ttg gat 528 Ile Ile Leu Glu Arg Leu Pro Cys Val Leu Gly Gly Val Gly Leu Asp 165 170 175 gat ctc ttt aag aac att ttt gtt aag gat ggg att ctg tcc ttc gaa 576 Asp Leu Phe Lys Asn Ile Phe Val Lys Asp Gly Ile Leu Ser Phe Glu 180 185 190 ggt att gcg aaa cct ctt ggt gac ctt ctc atc ctt gtc tta tgc ccg 624 Gly Ile Ala Lys Pro Leu Gly Asp Leu Leu Ile Leu Val Leu Cys Pro 195 200 205 aac gtc aag aat atc aat gta tcc tct 651 Asn Val Lys Asn Ile Asn Val Ser Ser 210 215 <210> 4 <211> 697 <212> DNA <213> Artificial sequence <220> CDS <223> SEQ ID NO: 3, which comprises a restriction site for NdeI, a coding sequence for a polyhistidine tag, a restriction site for EcoRI, a sequence encoding a cleavage site for TEV, a restriction site for NdeI, and a restriction site for XhoI <400> 4 g aat tct gaa aac ttg tat ttc cag ggc agc cat atg atg ctg ctg 46 Asn Ser Glu Asn Leu Tyr Phe Gln Gly Ser His Met Met Leu Leu 1 5 10 15 gaa ggt ttt ctg gtt ggg ggc ggt gtt ccg ggt cca ggc acg gcc tgc 94 Glu Gly Phe Leu Val Gly Gly Gly Val Pro Gly Pro Gly Thr Ala Cys 20 25 30 ttg acg aag gct ctg aaa gat agc ggt gac ctg ctg gtg gag tta gcg 142 Leu Thr Lys Ala Leu Lys Asp Ser Gly Asp Leu Leu Val Glu Leu Ala 35 40 45 gtt att att tgt gca tac cag aat ggc aaa gac ctt cag gag cag gac 190 Val Ile Ile Cys Ala Tyr Gln Asn Gly Lys Asp Leu Gln Glu Gln Asp 50 55 60 ttc aaa gaa ctg aag gaa ttg ctg gaa cgt aca ttg gaa cgt gcc ggt 238 Phe Lys Glu Leu Lys Glu Leu Leu Glu Arg Thr Leu Glu Arg Ala Gly 65 70 75 tgt gcc ctc gat gat to gtg gcc gat tta ggt ctg gaa gaa ctg ctg 286 Cys Ala Leu Asp Asp Ile Val Ala Asp Leu Gly Leu Glu Glu Leu Leu 80 85 90 95 ggc tcc atc ggc gtt agt acc ggc gat att atc cag ggt ctg tat aaa 334 Gly Ser Ile Gly Val Ser Thr Gly Asp Ile Ile Gln Gly Leu Tyr Lys 100 105 110 ctg ttg aag gag tta aaa atc gac gag acc gtc ttt aat gcg gtc tgc 382 Leu Leu Lys Glu Leu Lys Ile Asp Glu Thr Val Phe Asn Ala Val Cys 115 120 125 gat gtg acc aaa aaa atg ctg gat aac aag tgc tta ccg aaa att ctg 430 Asp Val Thr Lys Lys Met Leu Asp Asn Lys Cys Leu Pro Lys Ile Leu 130 135 140 caa gga gat ctg gta aag ttc ctt gat ctg aag tat aaa gtt tgt att 478 Gln Gly Asp Leu Val Lys Phe Leu Asp Leu Lys Tyr Lys Val Cys Ile 145 150 155 gaa ggt ggc gat cca gaa ctg att att aag gat ctg aaa atc atc ctg 526 Glu Gly Gly Asp Pro Glu Leu Ile Ile Lys Asp Leu Lys Ile Ile Leu 160 165 170 175 gaa cgg ctt ccg tgt gtg ttg ggt gga gtc ggt ttg gat gat ctc ttt 574 Glu Arg Leu Pro Cys Val Leu Gly Gly Val Gly Leu Asp Asp Leu Phe 180 185 190 aag aac att ttt gtt aag gat ggg att ctg tcc ttc gaa ggt att gcg 622 Lys Asn Ile Phe Val Lys Asp Gly Ile Leu Ser Phe Glu Gly Ile Ala 195 200 205 aaa cct ctt ggt gac ctt ctc atc ctt gtc tta tgc ccg aac gtc aag 670 Lys Pro Leu Gly Asp Leu Leu Ile Leu Val Leu Cys Pro Asn Val Lys 210 215 220 aat atc aat gta tcc tct taactcgag 697 Asn Ile Asn Val Ser Ser 225 <210> 5 <211> 6395 <212> DNA <213> Artificial sequence <220> <223> pPBUFCBac-LvRsn1 expression vector generated by inserting SEQ ID NO: 4 into SEQ ID NO: 5 <400> 5 gatctcgatc ccgcgaaatt aatacgactc actatagggg aattgtgagc ggataacaat 60 tcccctctag aaataatttt gtttaaactt taagaaggag atatacatat g cat cat 117 His His 1 cat cat cat cac gtg aat tct gaa aac ttg tat ttc cag ggc agc cat 165 His His His His Val Asn Ser Glu Asn Leu Tyr Phe Gln Gly Ser His 5 10 15 atg atg ctg ctg gaa ggt ttt ctg gtt ggg ggc ggt gtt ccg ggt cca 213 Met Met Leu Leu Glu Gly Phe Leu Val Gly Gly Gly Val Pro Gly Pro 20 25 30 ggc acg gcc tgc ttg acg aag gct ctg aaa gat agc ggt gac ctg ctg 261 Gly Thr Ala Cys Leu Thr Lys Ala Leu Lys Asp Ser Gly Asp Leu Leu 35 40 45 50 gtg gag tta gcg gtt att att tgt gca tac cag aat ggc aaa gac ctt 309 Val Glu Leu Ala Val Ile Ile Cys Ala Tyr Gln Asn Gly Lys Asp Leu 55 60 65 cag gag cag gac ttc aaa gaa ctg aag gaa ttg ctg gaa cgt aca ttg 357 Gln Glu Gln Asp Phe Lys Glu Leu Lys Glu Leu Leu Glu Arg Thr Leu 70 75 80 gaa cgt gcc ggt tgt gcc ctc gat gat att gtg gcc gat tta ggt ctg 405 Glu Arg Ala Gly Cys Ala Leu Asp Asp Ile Val Ala Asp Leu Gly Leu 85 90 95 gaa gaa ctg ctg ggc tcc atc ggc gtt agt acc ggc gat att atc cag 453 Glu Glu Leu Leu Gly Ser Ile Gly Val Ser Thr Gly Asp Ile Ile Gln 100 105 110 ggt ctg tat aaa ctg ttg aag gag tta aaa atc gac gag acc gtc ttt 501 Gly Leu Tyr Lys Leu Leu Lys Glu Leu Lys Ile Asp Glu Thr Val Phe 115 120 125 130 aat gcg gtc tgc gat gtg acc aaa aaa atg ctg gat aac aag tgc tta 549 Asn Ala Val Cys Asp Val Thr Lys Lys Met Leu Asp Asn Lys Cys Leu 135 140 145 ccg aaa att ctg caa gga gat ctg gta aag ttc ctt gat ctg aag tat 597 Pro Lys Ile Leu Gln Gly Asp Leu Val Lys Phe Leu Asp Leu Lys Tyr 150 155 160 aaa gtt tgt att gaa ggt ggc gat cca gaa ctg att att aag gat ctg 645 Lys Val Cys Ile Glu Gly Gly Asp Pro Glu Leu Ile Ile Lys Asp Leu 165 170 175 aaa atc atc ctg gaa cgg ctt ccg tgt gtg ttg ggt gga gtc ggt ttg 693 Lys Ile Ile Leu Glu Arg Leu Pro Cys Val Leu Gly Gly Val Gly Leu 180 185 190 gat gat ctc ttt aag aac att ttt gtt aag gat ggg att ctg tcc ttc 741 Asp Asp Leu Phe Lys Asn Ile Phe Val Lys Asp Gly Ile Leu Ser Phe 195 200 205 210 gaa ggt att gcg aaa cct ctt ggt gac ctt ctc atc ctt gtc tta tgc 789 Glu Gly Ile Ala Lys Pro Leu Gly Asp Leu Leu Ile Leu Val Leu Cys 215 220 225 ccg aac gtc aag aat atc aat gta tcc tct taactcgaga tcgatgatat 819 Pro Asn Val Light Asn Ile Asn Val Ser Ser 230 235 tcgagcctag gtataatcgg atccggctgc taacaaagcc cgaaaggaag ctgagttggc 879 tgctgccacc gctgagcaat aactagcata accccttggg gcccttaaac gggtcttgag 939 gggttttttg ctgaaaggag gaactatatc cggatatccc gcaagaggcc cggcagtacc 999 ggcataacca agcctatgcc tacagcatcc agggtgacgg tgccgaggat gacgatgagc 1059 gcattgttag atttcataca cggtgcctga ctgcgttagc aatttaactg tgataaacta 1119 ccgcattaaa gctagcttat cgatgataag ctgtcaaaca tgagaattaa ttcttgaaga 1179 cgaaagggcc tcgtgatacg cctattttta taggttaatg tcatgataat aatggtttct 1239 tagacgtcag gtggcacttt tcggggaaat gtgcgcggaa cccctatttg tttatttttc 1299 taaatacatt caaatatgta tccgctcatg agacaataac cctgataaat gcttcaataa 1359 tattgaaaaa ggaagagtat gagtattcaa catttccgtg tcgcccttat tccctttttt 1419 gcggcatttt gccttcctgt ttttgctcac ccagaaacgc tggtgaaagt aaaagatgct 1479 gaagatcagt tgggtgcacg agtgggttac atcgaactgg atctcaacag cggtaagatc 1539 cttgagagtt ttcgccccga agaacgtttt ccaatgatga gcacttttaa agttctgcta 1599 tgtggcgcgg tattatcccg tgttgacgcc gggcaagagc aactcggtcg ccgcatacac 1659 tattctcaga atgacttggt tgagtactca ccagtcacag aaaagcatct tacggatggc 1719 atgacagtaa gagaattatg cagtgctgcc ataccatga gtgataacac tgcggccaac 1779 ttactctga caacgatcgg aggaccgaag gagctaccg ctttttgca caacatgggg 1839 gatcatgtaa ctcgccttga tcgttgggaa ccggagctga atgaagccat accaacgac 1899 gagcgtgaca ccacgatgcc tgcagcaatg gcaacaacgt tgcgcaact attackagc 1959 gaactactta ctctagcttc ccggcacaa ttaatagact ggatggaggc ggataagtt 2019 gcaggaccac ttctgcgctc ggcctccg gctggctggt ttattgctga taatctgga 2079 gccggtgagc gtgggtctcg cggtatcatt gcagcactgg ggccagatgg taagccctcc 2139 cgtatcgtag ttactacac gacggggagt caggcaacta tggatgaacg aaatagacag 2199 atcgctgaga taggtgccctc actgattaag cattgtaac tgtcagacca agtttactca 2259 tatatacttt agattgatt aaacttcat ttttaattta aaaggatcta ggtgaagagatc 2319 ctttttgata atctcatgac caaatccct taacgtgagt ttcgttcca ctgagcgtca 2379 gaccccgtag aaagatcaa aggatctct tgagatcctt ttttctgcg cgtaatctgc 2439 tgcttgcaaa caaaaaaacc accgctacca gcggtggttt gtttgccgga tcaagagcta 2499 ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa tactgtcctt 2559 ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc tacatacctc 2619 gctctgctaa tcctgttacc agtggctgct gccagtggcg ataagtcgtg tcttaccggg 2679 ttggactcaa gacgatagtt accggataag gcgcagcggt cgggctgaac ggggggttcg 2739 tgcacacagc ccagcttgga gcgaacgacc tacaccgaac tgagatacct acagcgtgag 2799 ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc ggtaagcggc 2859 agggtcggaa caggagagcg cacgagggag cttccagggg gaaacgcctg gtatctttat 2919 agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg ctcgtcaggg 2979 gggcggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttcct ggccttttgc 3039 tggccttttg ctcacatgtt ctttcctgcg ttatcccctg attctgtgga taaccgtatt 3099 accgcctttg agtgagctga taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca 3159 gtgagcgagg aagcggaaga gcgcctgatg cggtattttc tccttacgca tctgtgcggt 3219 atttcacacc gcaatggtgc actctcagta caatctgctc tgatgccgca tagttaagcc agtatacact ccgctatcgc tacgtgactg ggtcatggct gcgccccgac acccgccaac acccgctgac gcgccctgac gggcttgtct gctcccggca tccgcttaca gacaagctgt 3399. 3459. gaccgtctcc gggagctgca tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag gcagctgcgg taaagctcat cagcgtggtc gtgaagcgat tcacagatgt ctgcctgttc atccgcgtcc agctcgttga gtttctccag aagcgttaat gtctggcttc tgataaagcg 3579. ggccatgtta agggcggttt tttcctgttt ggtcactgat gcctccgtgt aagggggatt 3639 tctgttcatg ggggtaatga taccgatga acgagagagg atgctcacga tacgggttac tgatgatgaa catgcccggt tactggaacg ttgtgagggt aaacaactgg cggtatggat gcggcgggac cagagaaaaa tcactcaggg tcaatgccag cgcttcgtta atacagatgt 3819 aggtgttcca cagggtagcc aggcatcc tgcgatgcag atccggaaca taatggtgca gggcgctgac ttccgcgttt ccagacttta cgaaacacgg aaaccgaaga ccattcatgt 3939 tgttgctcag gtcgcagacg ttttgcagca gcagtcgctt cacgttcgct cgcgtatcgg 3999 tgattcattc tgctaaccag taaggcaacc ccgccagcct agccgggtcc tcaacgacag 4059 gagcacgatc atgcgcaccc gtggccagga cccaacgctg cccgagatgc gccgcgtgcg 4119 gctgctggag atggcggacg cgatggatat gttctgccaa gggttggttt gcgcattcac 4179 agttctccgc aagaattgat tggctccaat tcttggagtg gtgaatccgt tagcgaggtg 4239 ccgccggctt ccattcaggt cgaggtggcc cggctccatg caccgcgacg caacgcgggg 4299 aggcagacaa ggtatagggc ggcgcctaca atccatgcca acccgttcca tgtgctcgcc 4359 gaggcggcat aaatcgccgt gacgatcagc ggtccaatga tcgaagttag gctggtaaga 4419 gccgcgagcg atccttgaag ctgtccctga tggtcgtcat ctacctgcct ggacagcatg 4479 gcctgcaacg cgggcatccc gatgccgccg gaagcgagaa gaatcataat ggggaaggcc 4539 atccagcctc gcgtcgcgaa cgccagcaag acgtagccca gcgcgtcggc cgccatgccg 4599 gcgataatgg cctgcttctc gccgaaacgt ttggtggcgg gaccagtgac gaaggcttga 4659 gcgagggcgt gcaagattcc gaataccgca agcgacaggc cgatcatcgt cgcgctccag 4719 cgaaagcggt cctcgccgaa aatgacccag agcgctgccg gcacctgtcc tacgagttgc 4779 atgataaaga agacagtcat aagtgcggcg acgatagtca tgccccgcgc ccaccggaag 4839 gagctgactg ggttgaaggc tctcaagggc atcggtcgag atcccggtgc ctaatgagtg 4899 agctaactta cattaattgc gttgcgctca ctgcccgctt tccagtcggg aaacctgtcg 4959 tgccagctgc attaatgaat cggccaacgc gcggggagag gcggtttgcg tattgggcgc 5019 cagggtggtt tttcttttca ccagtgagac gggcaacagc tgattgccct tcaccgcctg 5079 gccctgagag agttgcagca agcggtccac gctggtttgc cccagcaggc gaaaatcctg 5139 tttgatggtg gttaacggcg ggatataaca tgagctgtct tcggtatcgt cgtatcccac 5199 taccgagata tccgcaccaa cgcgcagccc ggactcggta atggcgcgca ttgcgcccag 5259 cgccatctga tcgttggcaa ccagcatcgc agtgggaacg atgccctcat tcagcatttg 5319 catggtttgt tgaaaccgga catggcactc cagtcgcctt cccgttccgc tatcggctga 5379 atttgattgc gagtgagata tttatgccag ccagccagac gcagacgcgc cgagacagaa 5439 cttaatgggc ccgctaacag cgcgatttgc tggtgaccca atgcgaccag atgctccacg 5499 cccagtcgcg taccgtcttc atgggagaaa ataatactgt tgatgggtgt ctggtcagag 5559 acatcaagaa ataacgccgg aacattagtg caggcagctt ccacagcaat ggcatcctgg 5619 tcatccagcg gatagttaat gatcagccca ctgacgcgtt gcgcgagaag attgtgcacc 5679 gccgctttac aggcttcgac gccgcttcgt tctaccatcg acaccaccac gctggcaccc 5739 agttgatcgg cgcgagattt aatcgccgcg acaatttgcg acggcgcgtg cagggccaga 5799 ctggaggtgg caacgccaat cagcaacgac tgtttgcccg ccagttgttg tgccacgcgg 5859 ttgggaatgt aattcagctc cgccatcgcc gcttccactt tttcccgcgt tttcgcagaa 5919 acgtggctgg cctggttcac cacgcgggaa acggtctgat aagagacacc ggcatactct 5979 gcgacatcgt ataacgttac tggtttcaca ttcaccaccc tgaattgact ctcttccggg 6039 cgctatcatg ccataccgcg aaaggttttg cgccattcga tggtgtccgg gatctcgacg 6099 ctctccctta tgcgactcct gcattaggaa gcagcccagt agtaggttga ggccgttgag 6159 caccgccgcc gcaaggaatg gtgcatgcaa ggagatggcg cccaacagtc ccccggccac 6219 ggggcctgcc accataccca cgccgaaaca agcgctcatg agcccgaagt ggcgagcccg 6279 atcttcccca tcggtgatgt cggcgatata ggcgccagca accgcacctg tggcgccggt 6339 gatgccggcc acgatgcgtc cggcgtagag gatcga 6375 <210> 6 <211> 236 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of a modified form of the Lv-Rsn-1 surfactant protein encoded by the nucleotide sequence SEQ ID NO: 4 comprising SEQ ID NO: 3 <400> 6 His His His His His Val Asn Ser Glu Asn Leu Tyr Phe Gln Gly 1 5 10 15 Ser His Met Met Leu Leu Glu Gly Phe Leu Val Gly Gly Gly Val Pro 20 25 30 Gly Pro Gly Thr Ala Cys Leu Thr Lys Ala Leu Lys Asp Ser Gly Asp 35 40 45 Leu Leu Val Glu Leu Ala Val Ile Ile Cys Ala Tyr Gln Asn Gly Lys 50 55 60 Asp Leu Gln Glu Gln Asp Phe Lys Glu Leu Lys Glu Leu Leu Glu Arg 65 70 75 80 Thr Leu Glu Arg Ala Gly Cys Ala Leu Asp Asp Ile Val Ala Asp Leu 85 90 95 Gly Leu Glu Glu Leu Leu Gly Ser Ile Gly Val Ser Thr Gly Asp Ile 100 105 110 Ile Gln Gly Leu Tyr Lys Leu Leu Lys Glu Leu Lys Ile Asp Glu Thr 115 120 125 Val Phe Asn Ala Val Cys Asp Val Thr Lys Lys Met Leu Asp Asn Lys 130 135 140 Cys Leu Pro Lys Ile Leu Gln Gly Asp Leu Val Lys Phe Leu Asp Leu 145 150 155 160 Lys Tyr Lys Val Cys Ile Glu Gly Gly Asp Pro Glu Leu Ile Ile Lys 165 170 175 Asp Leu Lys Ile Ile Leu Glu Arg Leu Pro Cys Val Leu Gly Gly Val 180 185 190 Gly Leu Asp Asp Leu Phe Lys Asn Ile Phe Val Lys Asp Gly Ile Leu 195 200 205 Ser Phe Glu Gly Ile Ala Lys Pro Leu Gly Asp Leu Leu Ile Leu Val 210 215 220 Leu Cys Pro Asn Val Lys Asn Ile Asn Val Ser Ser 225 230 235 <210> 7 <211> 648 <212> DNA <213> Artificial sequence <220> <221> CDS <222> (1)...(648) <223> Codon frequency optimization of SEQ ID NO: 2 for expression in yeast <400> 7 ttg ttg gaa gga ttt ttg gtc gga ggt ggt gtc cct ggt cct ggt aca 48 Leu Leu Glu Gly Phe Leu Val Gly Gly Gly Val Pro Gly Pro Gly Thr 1 5 10 15 gca tgt ttg act aag gca ttg aaa gac agt gga gac ttg ttg gtt gag 96 Ala Cys Leu Thr Lys Ala Leu Lys Asp Ser Gly Asp Leu Leu Val Glu 20 25 30 ttg gct gtt att att tgt gct tac caa aac ggt aaa gat ttg caa gag 144 Leu Ala Val Ile Ile Cys Ala Tyr Gln Asn Gly Lys Asp Leu Gln Glu 35 40 45 caa gat ttc aag gaa ttg aag gag ttg ttg gaa aga act ttg gaa aga 192 Gln Asp Phe Lys Glu Leu Lys Glu Leu Leu Glu Arg Thr Leu Glu Arg 50 55 60 gct ggt tgt gct ttg gat gat att gtt gct gat ttg ggt ttg gaa gag 240 Ala Gly Cys Ala Leu Asp Asp Ile Val Ala Asp Leu Gly Leu Glu Glu 65 70 75 80 ttg ttg ggt tct att ggt gtt tct act gga gat atc atc caa ggt ttg 288 Leu Leu Gly Ser Ile Gly Val Ser Thr Gly Asp Ile Ile Gln Gly Leu 85 90 95 tac aag ttg ttg aag gag ttg aag atc gat gaa act gtt ttt aac gct 336 Tyr Lys Leu Leu Lys Glu Leu Lys Ile Asp Glu Thr Val Phe Asn Ala 100 105 110 gtt tgt gat gtt act aag aaa atg ttg gat aac aag tgt ttg cca aag 384 Val Cys Asp Val Thr Lys Lys Met Leu Asp Asn Lys Cys Leu Pro Lys 115 120 125 atc ttg caa gga gat ttg gtt aag ttc ttg gat ttg aag tac aag gtt 432 Ile Leu Gln Gly Asp Leu Val Lys Phe Leu Asp Leu Lys Tyr Lys Val 130 135 140 tgt atc gaa ggt gga gat cca gaa ttg att att aag gat ttg aag atc 480 Cys Ile Glu Gly Gly Asp Pro Glu Leu Ile Ile Lys Asp Leu Lys Ile 145 150 155 160 atc ttg gag aga ttg cct tgt gtt ttg ggt ggt gtt ggt ttg gat gat 528 Ile Leu Glu Arg Leu Pro Cys Val Leu Gly Gly Val Gly Leu Asp Asp 165 170 175 ttg ttt aaa aac atc ttc gtt aag gat ggt att ttg tct ttc gaa ggt 576 Leu Phe Lys Asn Ile Phe Val Lys Asp Gly Ile Leu Ser Phe Glu Gly 180 185 190 att gct aag cct ttg gga gat ttg ttg att ttg gtt ttg tgt cct aat 624 Ile Ala Lys Pro Leu Gly Asp Leu Leu Ile Leu Val Leu Cys Pro Asn 195 200 205 gtc aag aat atc aat gtt tca tca 648 Val Light Asn Ile Asn Val Ser Ser 210 215 <210> 8 <211> 685 <212> DNA <213> Artificial sequence <220> <221> CDS <222> (1)...(648) <223> SEQ ID NO: 8 was obtained after adding a restriction site for the PstI endonuclease, two nucleotides to place the coding sequence in the same translation frame with secreted factor alpha, and a restriction site for the endonuclease NotI <400> 8 ct gca gga ttg ttg gaa gga ttt ttg gtc gga ggt ggt gtc cct ggt 47 Ala Gly Leu Leu Glu Gly Phe Leu Val Gly Gly Gly Val Pro Gly 1 5 10 15 cct ggt aca gca tgt ttg act aag gca ttg aaa gac agt gga gac ttg 95 Pro Gly Thr Ala Cys Leu Thr Lys Ala Leu Lys Asp Ser Gly Asp Leu 20 25 30 ttg gtt gag ttg gct gtt att att tgt gct tac caa aac ggt aaa gat 143 Leu Val Glu Leu Ala Val Ile Ile Cys Ala Tyr Gln Asn Gly Lys Asp 35 40 45 ttg caa gag caa gat ttc aag gaa ttg aag gag ttg ttg gaa aga act 191 Leu Gln Glu Gln Asp Phe Lys Glu Leu Lys Glu Leu Leu Glu Arg Thr 50 55 60 ttg gaa aga gct ggt tgt gct ttg gat gat att gtt gct gat ttg ggt 239 Leu Glu Arg Ala Gly Cys Ala Leu Asp Asp Ile Val Ala Asp Leu Gly 65 70 75 ttg gaa gag ttg ttg ggt tct att ggt gtt tct act gga gat atc atc 287 Leu Glu Glu Leu Leu Gly Ser Ile Gly Val Ser Thr Gly Asp Ile Ile 80 85 90 95 caa ggt ttg tac aag ttg ttg aag gag ttg aag atc gat gaa act gtt 335 Gln Gly Leu Tyr Lys Leu Leu Lys Glu Leu Lys Ile Asp Glu Thr Val 100 105 110 ttt aac gct gtt tgt gat gtt act aag aaa atg ttg gat aac aag tgt 383 Phe Asn Ala Val Cys Asp Val Thr Lys Lys Met Leu Asp Asn Lys Cys 115 120 125 ttg cca aag atc ttg caa gga gat ttg gtt aag ttc ttg gat ttg aag 431 Leu Pro Lys Ile Leu Gln Gly Asp Leu Val Lys Phe Leu Asp Leu Lys 130 135 140 tac aag gtt tgt atc gaa ggt gga gat cca gaa ttg att att aag gat 479 Tyr Lys Val Cys Ile Glu Gly Gly Asp Pro Glu Leu Ile Ile Lys Asp 145 150 155 ttg aag atc atc ttg gag aga ttg cct tgt gtt ttg ggt ggt gtt ggt 527 Leu Lys Ile Ile Leu Glu Arg Leu Pro Cys Val Leu Gly Gly Val Gly 160 165 170 175 ttg gat gat ttg ttt aaa aac atc ttc gtt aag gat ggt att ttg tct 575 Leu Asp Asp Leu Phe Lys Asn Ile Phe Val Lys Asp Gly Ile Leu Ser 180 185 190 ttc gaa ggt att gct aag cct ttg gga gat ttg ttg att ttg gtt ttg 623 Phe Glu Gly Ile Ala Lys Pro Leu Gly Asp Leu Leu Ile Leu Val Leu 195 200 205 tgt cct aat gtc aag aat atc aat gtt tca tca gag aac ctt tac ttt 671 Cys Pro Asn Val Lys Asn Ile Asn Val Ser Ser Glu Asn Leu Tyr Phe 210 215 220 cag gga gcg gcc gc 685 Gln Gly Ala Ala 225 <210> 9 <211> 4219 <212> DNA <213> Artificial sequence <220> <223> pPBUFCYea-LvRsn1 expression vector generated by inserting SEQ ID NO: 9 into SEQ ID NO: 10 <400> 9 agatctaaca tccaaagacg aaaggttgaa tgaaaccttt ttgccatccg acatccacag 60 gtccattctc acacataagt gccaaacgca acaggagggg atacactagc agcagaccgt 120 tgcaaacgca ggacctccac tcctcttctc ctcaacaccc acttttgcca tcgaaaaacc 180 agcccagtta ttgggcttga ttggagctcg ctcattccaa ttccttctat taggctacta 240 acaccatgac tttattagcc tgtctatcct ggcccccctg gcgaggttca tgtttgttta 300 tttccgaatg caacaagctc cgcattacac ccgaacatca ctccagatga gggctttctg 360 agtgtggggt caaatagttt catgttcccc aaatggccca aaactgacag tttaaacgct 420 gtcttggaac ctaatatgac aaaagcgtga tctcatccaa gatgaactaa gtttggttcg 480 ttgaaatgct aacggccagt tggtcaaaaa gaaacttcca aaagtcggca taccgtttgt 540 cttgtttggt attgattgac gaatgctcaa aaataatctc attaatgctt agcgcagtct 600 ctctatcgct tctgaacccc ggtgcacctg tgccgaaacg caaatgggga aacacccgct 660 ttttggatga ttatgcattg tctccacatt gtatgcttcc aagattctgg tgggaatact 720 <h2 style=";text-align:left;direction:ltr">gctgatagcc taacgttcat gatcaaaatt taactgttct aacccctact tgacagcaat 780<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> atataaacag aaggaagctg ccctgtctta aacctttttt tttatcatca ttattagctt 840<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> actttcataa ttgcgactgg ttccaattga caagcttttg attttaacga cttttaacga 900<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> caacttgaga agatcaaaaa acaactaatt attcgaaacg atg aga ttt cct tca 955<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Met Arg Phe Pro Ser<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 1 5<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> att ttt act gct gtt tta ttc gca gca tcc tcc gca tta gct gct cca 1003<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Ile Phe Thr Ala Val Leu Phe Ala Ala Ser Ser Ala Leu Ala Ala Pro<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 10 15 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> gtc aac act aca aca gaa gat gaa acg gca caa att ccg gct gaa gct 1051<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln Ile Pro Ala Glu Ala<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 25 30 35<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> gtc atc ggt tac tca gat tta gaa ggg gat ttc gat gtt gct gtt ttg 1099<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe Asp Val Ala Val Leu<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 40 45 50<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> cca ttt tcc aac agc aca aat aac ggg tta ttg ttt ata aat act act 1147<h2 style=";text-align:left;direction:ltr"> Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu Phe Ile Asn Thr Thr 55 60 65 att gcc agc att gct gct aaa gaa gaa ggg gta tct ctc gag aaa aga 1195 Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val Ser Leu Glu Lys Arg 70 75 80 85 gag gct gaa gct gca gga ttg ttg gaa gga ttt ttg gtc gga ggt ggt 1243 Glu Ala Glu Ala Ala Gly Leu Leu Glu Gly Phe Leu Val Gly Gly Gly 90 95 100 gtc cct ggt cct ggt aca gca tgt ttg act aag gca ttg aaa gac agt 1291 Val Pro Gly Pro Gly Thr Ala Cys Leu Thr Lys Ala Leu Lys Asp Ser 105 110 115 gga gac ttg ttg gtt gag ttg gct gtt att att tgt gct tac caa aac 1339 Gly Asp Leu Leu Val Glu Leu Ala Val Ile Ile Cys Ala Tyr Gln Asn 120 125 130 ggt aaa gat ttg caa gag caa gat ttc aag gaa ttg aag gag ttg ttg 1387 Gly Lys Asp Leu Gln Glu Gln Asp Phe Lys Glu Leu Lys Glu Leu Leu 135 140 145 gaa aga act ttg gaa aga gct ggt tgt gct ttg gat gat att gtt gct 1435 Glu Arg Thr Leu Glu Arg Ala Gly Cys Ala Leu Asp Asp Ile Val Ala 150 155 160 165 gat ttg ggt ttg gaa gag ttg ttg ggt tct att ggt gtt tct act gga 1483 Asp Leu Gly Leu Glu Glu Leu Leu Gly Ser Ile Gly Val Ser Thr Gly 170 175 180 gat atc atc caa ggt ttg tac aag ttg ttg aag gag ttg aag atc gat 1531 Asp Ile Ile Gln Gly Leu Tyr Lys Leu Leu Lys Glu Leu Lys Ile Asp 185 190 195 gaa act gtt ttt aac gct gtt tgt gat gtt act aag aaa atg ttg gat 1579 Glu Thr Val Phe Asn Ala Val Cys Asp Val Thr Lys Lys Met Leu Asp 200 205 210 aac aag tgt ttg cca aag atc ttg caa gga gat ttg gtt aag ttc ttg 1627 Asn Lys Cys Leu Pro Lys Ile Leu Gln Gly Asp Leu Val Lys Phe Leu 215 220 225 gat ttg aag tac aag gtt tgt atc gaa ggt gga gat cca gaa ttg att 1675 Asp Leu Lys Tyr Lys Val Cys Ile Glu Gly Gly Asp Pro Glu Leu Ile 230 235 240 245 att aag gat ttg aag atc atc ttg gag aga ttg cct tgt gtt ttg ggt 1723 Ile Lys Asp Leu Lys Ile Ile Leu Glu Arg Leu Pro Cys Val Leu Gly 250 255 260 ggt gtt ggt ttg gat gat ttg ttt aaa aac atc ttc gtt aag gat ggt 1771 Gly Val Gly Leu Asp Asp Leu Phe Lys Asn Ile Phe Val Lys Asp Gly 265 270 275 att ttg tct ttc gaa ggt att gct aag cct ttg gga gat ttg ttg att 1819 Ile Leu Ser Phe Glu Gly Ile Ala Lys Pro Leu Gly Asp Leu Leu Ile 280 285 290 ttg gtt ttg tgt cct aat gtc aag aat atc aat gtt tca tca gag aac 1867 Leu Val Leu Cys Pro Asn Val Lys Asn Ile Asn Val Ser Ser Glu Asn 295 300 305 ctt tac ttt cag gga gcg gcc gcc agc ttt cta gaa caa aaa ctc atc 1915 Leu Tyr Phe Gln Gly Ala Ala Ala Ser Phe Leu Glu Gln Lys Leu Ile 310 315 320 325 tca gaa gag gat ctg aat agc gcc gc gac cat cat cat cat cat cat 1963 Ser Glu Glu Asp Leu Asn Ser Ala Val Asp His His His His His 330 335 340 tgagtttgta gccttagaca tgactgttcc tcagttcaag ttgggcactt acgagaagac 2023 cggtcttgct agattctaat caagaggatg tcagaatgcc atttgcctga gagatgcagg 2083 cttcattttt gatacttttt tatttgtaac ctatatagta taggattttt tttgtcattt 2143 tgttcttct cgtacgagct tgctcctgat cagcctatct cgcagctgat gaatatcttg 2203 tggtaggggt ttgggaaaat cattcgagtt tgatgttttt cttggtattt cccactcctc 2263 ttcagagtac agaagattaa gtgagacctt cgtttgtgcg gatcccccac acaccatagc 2323 ttcaaaatgt ttctactcct ttttactct tccagattttt ctcggactcc gcgcatcgcc 2383 gtaccacttc aaaacaccca agcacagcat actaaatttt ccctctttct tcctctaggg 2443 tgtcgttaat tacccgtact aaaggtttgg aaaagaaaaa agagaccgcc tcgtttcttt 2503 ttcttcgtcg aaaaaggcaa taaaaatttt tatcacgttt ctttttcttg aaattttttt 2563 ttttagtttt tttctctttc agtgacctcc attgatattt aagttaataa acggtcttca 2623 atttctcaag tttcagtttc atttttcttg ttctattaca acttttttta cttcttgttc 2683 attagaaaga aagcatagca atctaatcta aggggcggtg ttgacaatta atcatcggca 2743 tagtatatcg gcatagtata atacgacaag gtgaggaact aaaccatggc caagttgacc 2803 agtgccgttc cggtgctcac cgcgcgcgac gtcgccggag cggtcgagtt ctggaccgac 2863 cggctcgggt tctcccggga cttcgtggag gacgacttcg ccggtgtggt ccgggacgac 2923 gtgaccctgt tcatcagcgc ggtccaggac caggtggtgc cggacaacac cctggcctgg 2983 gtgtgggtgc gcggcctgga cgagctgtac gccgagtggt cggaggtcgt gtccacgaac 3043 ttccgggacg cctccgggcc ggccatgacc gagatcggcg agcagccgtg ggggcgggag 3103 ttcgccctgc gcgacccggc cggcaactgc gtgcacttcg tggccgagga gcaggactga 3163 cacgtccgac ggcggcccac gggtcccagg cctcggagat ccgtccccct tttcctttgt 3223 cgatatcatg taattagtta tgtcacgctt acattcacgc cctcccccca catccgctct 3283 aaccgaaaag gaaggagtta gacaacctga agtctaggtc cctatttatt tttttatagt 3343 tatgttagta ttaagaacgt tatttatatt tcaaattttt cttttttttc tgtacagacg 3403 cgtgtacgca tgtaacatta tactgaaaac cttgcttgag aaggttttgg gacgctcgaa 3463 ggctttaatt tgcaagctgg agaccaacat gtgagcaaaa ggccagcaaa aggccaggaa 3523 ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cgcccccctg acgagcatca 3583 caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc 3643 gttccccct ggaagctccc tcgtgcgctc tcctgttccg acctgccgc ttaccggata 3703 cctgtccgcc tttctccctt cgggaagcgt ggcgctttct caatgctcac gctgtaggta 3763 tctcagttcg gtgtagtcg ttcgctccaa gctgggctgt gtgcacgaac cccccgttca 3823 gcccgaccgc tgcgccttat ccggtaacta tcgtcttgag tccaacccgg taagacacga 3883 cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg 3943 tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatttgg 4003 tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg 4063 caaacaaacc accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag 4123 aaaaaaagga tctcaagaag atcctttgat cttttctacg gggtctgacg ctcagtggaa 4183 cgaaaactca cgttaaggga ttttggtcat gagatc 4219 <210> 10 <211> 341 <212> PRT <213> Artificial sequence <220> <223> The amino acid sequence of the modified form of the Lv-Rsn-1 surfactant protein encoded by the nucleotide sequence SEQ ID NO: 9, which in turn is contained in SEQ ID NO: 11. <400> 10 Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala Ser Ser 1 5 10 15 Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln 20 25 30 Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe 35 40 45 Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu 50 55 60 Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val 65 70 75 80 Ser Leu Glu Lys Arg Glu Ala Glu Ala Ala Gly Leu Leu Glu Gly Phe 85 90 95 Leu Val Gly Gly Gly Val Pro Gly Pro Gly Thr Ala Cys Leu Thr Lys 100 105 110 Ala Leu Lys Asp Ser Gly Asp Leu Leu Val Glu Leu Ala Val Ile Ile 115 120 125 Cys Ala Tyr Gln Asn Gly Lys Asp Leu Gln Glu Gln Asp Phe Lys Glu 130 135 140 Leu Lys Glu Leu Leu Glu Arg Thr Leu Glu Arg Ala Gly Cys Ala Leu 145 150 155 160 Asp Asp Ile Val Ala Asp Leu Gly Leu Glu Glu Leu Leu Gly Ser Ile 165 170 175 Gly Val Ser Thr Gly Asp Ile Ile Gln Gly Leu Tyr Lys Leu Leu Lys 180 185 190 Glu Leu Lys Ile Asp Glu Thr Val Phe Asn Ala Val Cys Asp Val Thr 195 200 205 Lys Lys Met Leu Asp Asn Lys Cys Leu Pro Lys Ile Leu Gln Gly Asp 210 215 220 Leu Val Lys Phe Leu Asp Leu Lys Tyr Lys Val Cys Ile Glu Gly Gly 225 230 235 240 Asp Pro Glu Leu Ile Ile Lys Asp Leu Lys Ile Ile Leu Glu Arg Leu 245 250 255 Pro Cys Val Leu Gly Gly Val Gly Leu Asp Asp Leu Phe Lys Asn Ile 260 265 270 Phe Val Lys Asp Gly Ile Leu Ser Phe Glu Gly Ile Ala Lys Pro Leu 275 280 285 Gly Asp Leu Leu Ile Leu Val Leu Cys Pro Asn Val Lys Asn Ile Asn 290 295 300 Val Ser Ser Glu Asn Leu Tyr Phe Gln Gly Ala Ala Ala Ser Phe Leu 305 310 315 320 Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Ser Ala Val Asp His 325 330 335 His His His His His 340
Claims
1. A polynucleotide, characterized in that the polynucleotide encodes the predicted sequence of a surfactant protein Lv-ranaspumin-1 (Lv-Rsn-1) isoform and consists of SEQ ID NO:
2.
2. A polynucleotide, characterized in that the polynucleotide encodes the predicted sequence of a surfactant protein Lv-ranaspumin-1 (Lv-Rsn-1) isoform, and characterized in that the polynucleotide has a codon frequency optimized for expression in bacteria and consists of SEQ ID NO:
3.
3. A polynucleotide, characterized in that the polynucleotide encodes the predicted sequence of a surfactant protein Lv-ranaspumin-1 (Lv-Rsn-1) isoform, and characterized in that the polynucleotide has a codon frequency optimized for expression in yeast and consists of SEQ ID NO:
7.
4. A polypeptide, characterized in that the polypeptide is a modified form of the surfactant protein Lv-ranaspumin-1 (Lv-Rsn-1) isoform and consists of SEQ ID NO:
6.
5. A polypeptide, characterized in that the polypeptide is a modified form of the surfactant protein Lv-ranaspumin-1 (Lv-Rsn-1) isoform and consists of SEQ ID NO:
10.
6. An expression cassette, characterized in that the expression cassette comprises the polynucleotide according to claim 2, which is operably linked to a promoter that directs expression in bacteria.
7. An expression cassette, characterized in that the expression cassette comprises the polynucleotide according to claim 3, which is operably linked to a promoter that directs expression in fungi.
8. The expression cassette according to claim 7, characterized in that the fungus is yeast.
9. An expression vector, characterized in that the expression vector comprises the expression cassette according to claim 6.
10. An expression and transformation vector, characterized in that the expression and transformation vector comprises the expression cassette according to claim 7 or 8.
11. A genetically modified microorganism, characterized in that the genetically modified microorganism is a bacterium that produces such a protein: the coding sequence of the protein comprises the polynucleotide according to claim 6.
12. A genetically modified microorganism, characterized in that the genetically modified microorganism is a yeast that produces such a protein: the coding sequence of the protein comprises the polynucleotide according to claim 7 or 8.
13. A method for producing a genetically modified organism, characterized in that the method produces a bacterium according to claim 11 and include: a) transforming a bacterial strain with the expression cassette according to claim 6; b) Selecting transformed bacteria.
14. A method for producing a genetically modified organism, characterized in that the method produces the yeast according to claim 12 and include: a) transforming a yeast strain with the expression cassette according to claim 7 or 8; b) Selection of transformed yeast.
15. Bioproduct, characterized in that it comprises the polypeptide according to claim 4.
16. Bioproduct, characterized in that it comprises the polypeptide according to claim 5.
17. An oil recovery method comprising using a biosurfactant protein obtained from a genetically modified organism, wherein the biosurfactant protein is a polypeptide encoded by a polynucleotide according to claims 1 to 3, or a polypeptide according to claims 4 to 5, characterized in that the genetically modified organism is capable of synthesizing the biosurfactant protein Lv-ranaspumin-1.
18. A method for improving reservoir fluid dynamics, comprising using a biosurfactant protein obtained from a genetically modified organism, wherein the biosurfactant protein is a polypeptide encoded by a polynucleotide according to claims 1 to 3, or a polypeptide according to claims 4 to 5, characterized in that the genetically modified organism is capable of synthesizing the biosurfactant protein Lv-ranaspumin-1.
19. A method for oil bioremediation, comprising using a biosurfactant protein obtained from a genetically modified organism, wherein the biosurfactant protein is a polypeptide encoded by a polynucleotide according to claims 1 to 3, or a polypeptide according to claims 4 to 5, characterized in that the genetically modified organism is capable of synthesizing the biosurfactant protein Lv-ranaspumin-1.
20. A tank cleaning method in the oil and gas industry, comprising using a biosurfactant protein obtained from a genetically modified organism, wherein the biosurfactant protein is a polypeptide encoded by a polynucleotide according to claims 1 to 3, or a polypeptide according to claims 4 to 5, characterized in that the genetically modified organism is capable of synthesizing the biosurfactant protein Lv-ranaspumin-1.
